A Phase 1b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Latest Information Update: 06 May 2024
At a glance
- Drugs Picibanil (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- Acronyms ADVANCED-1 (phase 1b); ADVANCED-1EXP
- Sponsors Protara Therapeutics
- 05 Apr 2024 Positive 3-month data presented in a Protara Therapeutics Media Release.
- 04 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Aug 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.